”If Foxy-5 – besides its anti-metastatic qualities – can be combined and function well together with new immunotherapies, further interesting possibilities open up for the drug candidate to become a key component in treating cancer in the future” says Henrik Lawaetz, CEO, WntResearch AB.

The aim of the collaboration, which is based on pre-clinical experimental models, is to increase the knowledge base about important immunological factors connected to metastasis and how Foxy-5 can affect these factors.

For further information contact:

Henrik Lawaetz, CEO
E-mail: hl@wntresearch.com
Telephone: +46 72 702 4694

The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on February 3, 2017.

About WntResearch

WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastasises and the need for a specific treatment to counteract metastasis is therefore in high demand.

WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1 study show a favourable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden. For further information: www.wntresearch.com